RedHill Biopharma (RDHL)
NASDAQ:RDHL
Want to see RDHL full AI Analyst Report?
Total Valuation
RedHill Biopharma has a market cap or net worth of $5.30M. The enterprise value is $811.05K.
Market Cap$5.30M
Enterprise Value$811.05K
Share Statistics
RedHill Biopharma has 5,191,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,191,260
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
RedHill Biopharma’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee8.17K
Profits Per Employee-12.26K
Employee Count35
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of RedHill Biopharma is ―. RedHill Biopharma’s PEG ratio is 0.00.
PE Ratio―
PS Ratio1.72
PB Ratio-0.79
Price to Fair Value―
Price to FCF-1.39
Price to Operating Cash Flow-0.30
PEG Ratio0.00
Income Statement
In the last 12 months, RedHill Biopharma had revenue of 286.00K and earned -429.00K in profits. Earnings per share was 0.00.
Revenue286.00K
Gross Profit286.00K
Operating Income-7.91M
Pretax Income-8.08M
Net Income-429.00K
EBITDA-7.65M
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was -8.20M and capital expenditures -12.00K, giving a free cash flow of -8.21M billion.
Operating Cash Flow-8.20M
Free Cash Flow-8.21M
Free Cash Flow per Share-1.58
Dividends & Yields
RedHill Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.53
52-Week Price Change-49.30%
50-Day Moving Average0.90
200-Day Moving Average1.31
Relative Strength Index (RSI)42.60
Average Volume (3m)1.98M
Important Dates
RedHill Biopharma upcoming earnings date is Aug 13, 2026, TBA (Confirmed).
Last Earnings DateMar 12, 2026
Next Earnings DateAug 13, 2026
Ex-Dividend Date―
Financial Position
RedHill Biopharma as a current ratio of ―, with Debt / Equity ratio of 25.07%
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, RedHill Biopharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate―
Enterprise Valuation
RedHill Biopharma EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
RedHill Biopharma has $2.87M in cash and marketable securities with $214.00K in debt, giving a net cash position of $2.65M billion.
Cash & Marketable Securities$2.87M
Total Debt$214.00K
Net Cash$2.65M
Net Cash Per Share$0.51
Tangible Book Value Per Share―
Margins
Gross margin is 63.30%, with operating margin of ―, and net profit margin of ―.
Gross Margin63.30%
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for RedHill Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―